Clinical Trials Browser

Withdrawn × Breast Neoplasms × Erlotinib Hydrochloride × Clear all

NCT01013506 2013-05-23

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms